Policy | January 01, 2026
Govt. issues draft amendment to remove cough syrups from Schedule K
Once finalized, cough syrups will no longer be available for over-the-counter sale
Once finalized, cough syrups will no longer be available for over-the-counter sale
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Applications include detailed scientific rationale and supporting clinical evidence
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
